Epirubicin plus temozolomide effective in leiomyosarcoma
Epirubicin combined with temozolomide (EPI-TMZ) is effective in patients with advanced leiomyosarcoma (LMS) and has tolerable adverse effects, according to a study.
The outcomes reported in this study appear to be better than previous studies of other treatments for advanced LMS, which show a best median progression-free survival (PFS) time of 9.2 months and a best overall response rate (ORR) was 30.9%.
In this retrospective study, 15 patients who received EPI-TMZ for LMS, including 6 as a first-line treatment, 7 as a second- or third-line treatment, and 2 as a fourth-line treatment, were included.
At the data cutoff, median PFS was 10 months, overall response rate was 53.3%, and disease control rate was 100%. One patient had clinical complete response, 7 had partial response, and 7 had stable disease.
The most common treatment-related adverse effects were leukopenia, neutropenia, thrombocytopenia, anemia, nausea, vomiting, fatigue, and oral mucositis, with 1 patient having severe adverse effects. There were no treatment-related deaths.
Tan H, Zuo L, Ma S, et al. Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma. Cancer Manag Res. 2021;13:9075-9083. doi: 10.2147/CMAR.S342213. PMID: 34916850; PMCID: PMC8672029.